Ajanta Pharma

₹2375.5 -34.6 | 1.4%

WEBSITE BSE:532331 NSE : AJANTA PHARM 10 May, 16:01

Market Cap ₹29912 Cr.

Stock P/E 36.8

P/B 8.4

Current Price ₹2375.5

Book Value ₹ 283.3

Face Value 2

52W High ₹2532

Dividend Yield 0.29%

52W Low ₹ 1240.6

Edit Ratio

Ajanta Pharma Research see more...

Overview Inc. Year: 1979Industry: Pharmaceuticals & Drugs

Ajanta Pharma Ltd is a holding company. The Company is a specialty pharmaceutical company engaged in growing, generating and advertising and marketing a variety of branded and usual formulations. Its business consists of branded generics in rising markets of Asia and Africa, generics inside the developed markets of the USA and Institutional sales. The branded generics business is spread in India and over 30 rising nations across Africa, Commonwealth of Independent States (CIS), the Middle East and South East Asia. The Company serves various therapeutic segments, including anti-biotic, anti-malarial, anti-diabetic, cardiology, gynaecology, orthopaedics, paediatric, respiratory and fashionable fitness merchandise. Ajanta has six formulations manufacturing centers placed in India and 1 in Mauritius. In addition, the Company also has an API production facility located at Waluj, India. The Company's subsidiaries encompass Ajanta Pharma (Mauritius) Ltd., and Ajanta Pharma USA Inc.

Ajanta Pharma Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Ajanta Pharma Quarterly Results

#(Fig in Cr.)	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Net Sales	838	870	951	938	972	882	1021	1028	1105	1054
Other Income	24	29	33	40	35	37	32	21	14	36
Total Income	862	900	984	978	1007	919	1053	1050	1119	1090
Total Expenditure	598	664	729	742	802	732	750	738	791	776
Operating Profit	264	236	255	237	204	186	303	312	328	314
Interest	1	7	1	1	3	1	1	2	2	2
Depreciation	32	31	32	33	33	33	33	34	34	34
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	231	198	222	203	168	152	269	276	291	278
Provision for Tax	39	46	47	46	34	30	61	81	81	75
Profit After Tax	192	151	175	157	135	122	208	195	210	203
Adjustments	0	0	0	0	0	0	0	0	0	0
Profit After Adjustments	192	151	175	157	135	122	208	195	210	203
Adjusted Earnings Per Share	14.7	11.7	13.6	12.2	10.5	9.7	16.5	15.5	16.6	16

Ajanta Pharma Profit & Loss

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	TTM
Net Sales	931	1208	1474	1734	1983	2126	2055	2588	2890	3341	3743	4208
Other Income	6	14	17	21	24	24	21	92	26	116	99	103
Total Income	936	1222	1490	1755	2007	2150	2076	2680	2916	3457	3841	4312
Total Expenditure	706	840	968	1147	1296	1467	1489	1905	1891	2412	2959	3055
Operating Profit	230	382	522	608	711	683	588	776	1025	1045	882	1257
Interest	19	9	6	5	1	0	1	12	8	10	6	7
Depreciation	34	44	52	44	61	60	72	96	116	125	131	135
Exceptional Income / Expenses	0	0	-8	0	0	0	0	-4	0	0	0	0
Profit Before Tax	177	330	456	559	648	623	514	664	900	909	745	1114
Provision for Tax	65	96	146	143	141	154	127	196	246	197	157	298
Profit After Tax	112	234	310	416	507	469	387	468	654	713	588	816
Adjustments	0	0	0	0	0	0	0	0	0	0	0	0
Profit After Adjustments	112	234	310	416	507	469	387	468	654	713	588	816
Adjusted Earnings Per Share	8.5	17.7	23.5	31.5	38.4	35.5	29.6	35.7	50.4	55.6	46.7	64.6

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	12%	13%	12%	15%
Operating Profit CAGR	-16%	4%	5%	14%
PAT CAGR	-18%	8%	5%	18%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	88%	21%	27%	24%
ROE Average	18%	21%	20%	30%
ROCE Average	23%	28%	27%	38%

Ajanta Pharma Balance Sheet

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Shareholder's Funds	393	593	841	1191	1568	2041	2245	2599	2996	3264	3388
Minority's Interest	0	0	0	0	0	0	0	0	0	0	0
Borrowings	73	52	33	15	1	1	1	1	2	2	1
Other Non-Current Liabilities	29	28	22	14	8	38	162	227	273	283	176
Total Current Liabilities	222	275	250	260	247	346	498	746	839	647	1139
Total Liabilities	718	949	1146	1479	1823	2426	2906	3572	4109	4197	4705
Fixed Assets	273	279	288	451	589	1053	1168	1463	1532	1504	1496
Other Non-Current Assets	77	150	225	265	383	150	437	328	359	429	374
Total Current Assets	369	520	633	763	851	1224	1301	1781	2218	2264	2825
Total Assets	718	949	1146	1479	1823	2426	2906	3572	4109	4197	4705

Ajanta Pharma Cash Flow

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Opening Cash & Cash Equivalents	8	34	39	42	41	66	91	95	202	178	206
Cash Flow from Operating Activities	234	212	279	326	609	281	375	457	576	562	792
Cash Flow from Investing Activities	-104	-188	-158	-209	-383	-256	-223	-224	-282	-74	-560
Cash Flow from Financing Activities	-104	-20	-105	-117	-202	-0	-147	-129	-318	-460	-108
Net Cash Inflow / Outflow	26	4	16	-0	24	25	4	104	-24	28	124
Closing Cash & Cash Equivalent	34	39	54	41	66	91	95	199	178	205	331

Ajanta Pharma Ratios

#	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Earnings Per Share (Rs)	8.51	17.74	23.49	31.49	38.4	35.5	29.57	35.74	50.39	55.63	46.7
CEPS(Rs)	11.1	21.07	27.4	34.85	43.03	40.02	35.08	43.05	59.34	65.42	57.09
DPS(Rs)	2.5	4	6	8	13	0	9	13	9.5	9.5	7
Book NAV/Share(Rs)	29.82	44.95	63.72	90.19	118.63	154.52	171.46	198.53	230.83	254.8	269.07
Core EBITDA Margin(%)	23.96	30.33	34.02	33.56	34.32	30.9	27.56	26.4	33.85	27.37	20.64
EBIT Margin(%)	20.91	27.84	31.1	32.23	32.45	29.24	25.08	26.12	30.8	27.09	19.79
Pre Tax Margin(%)	18.87	27.13	30.7	31.95	32.38	29.22	25.02	25.66	30.52	26.78	19.63
PAT Margin (%)	11.97	19.23	20.86	23.76	25.32	21.99	18.83	18.07	22.17	20.99	15.49
Cash Profit Margin (%)	15.61	22.84	24.34	26.3	28.38	24.79	22.33	21.77	26.1	24.68	18.94
ROA(%)	16.4	28.05	29.57	31.66	30.69	22.06	14.52	14.44	17.03	17.16	13.21
ROE(%)	32.46	47.47	43.24	40.93	36.77	26	18.07	19.32	23.38	22.77	17.68
ROCE(%)	38.57	54.52	56.43	51.59	45.72	34.49	23.84	27.44	32.2	29.37	22.57
Receivable days	56.78	52.93	56.64	65.84	63.41	67.06	81.62	87.08	93.66	94.5	99.85
Inventory Days	61.44	45.48	38.64	37.93	37.89	48.1	69.82	65.68	78.09	83.71	77.25
Payable days	170.04	164.68	146.84	146.44	183.16	246.02	293.02	199.39	260.89	188.77	157.44
PER(x)	13.44	15.05	34.78	29.87	30.56	26.4	23.23	25.49	23.72	21.68	25.89
Price/Book(x)	3.84	5.94	12.82	10.43	9.89	6.07	4.01	4.59	5.18	4.73	4.49
Dividend Yield(%)	0.97	1	0.49	0.57	0.74	0	0.87	0.95	0.53	0.53	0.58
EV/Net Sales(x)	1.7	2.97	7.27	7.18	7.78	5.78	4.34	4.54	5.3	4.56	3.98
EV/Core EBITDA(x)	6.89	9.39	20.52	20.47	21.7	17.99	15.19	15.16	14.94	14.58	16.89
Net Sales Growth(%)	37.42	29.81	21.95	17.67	14.38	7.19	-3.31	25.91	11.66	15.62	12.02
EBIT Growth(%)	84.17	72.82	36.43	22.05	15.21	-4.09	-17.26	31.13	34.41	1.24	-18.33
PAT Growth(%)	45.11	108.62	32.49	34.13	21.95	-7.54	-17.43	20.86	39.81	8.99	-17.5
EPS Growth(%)	45.11	108.44	32.41	34.05	21.95	-7.54	-16.72	20.86	41.02	10.4	-16.06
Debt/Equity(x)	0.32	0.22	0.09	0.07	0	0	0.02	0.02	0	0	0
Current Ratio(x)	1.66	1.89	2.54	2.94	3.45	3.54	2.61	2.39	2.64	3.5	2.48
Quick Ratio(x)	1	1.32	1.9	2.15	2.65	2.54	1.8	1.73	1.74	2.31	1.77
Interest Cover(x)	10.24	38.78	78.03	115.29	477.6	1519.41	444.34	56.75	109.85	90.16	128.61
Total Debt/Mcap(x)	0.08	0.04	0.01	0.01	0	0	0	0	0	0	0

Ajanta Pharma Shareholding Pattern

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	70.34	70.48	70.48	70.48	66.11	66.11	66.21	66.21	66.21	66.21
FII	8.95	8.64	8.3	8.23	10.07	10	10.19	9.99	9.11	8.54
DII	12.59	12.74	12.91	13.14	15.82	15.98	15.81	15.59	16.67	17.49
Public	8.12	8.14	8.31	8.15	8	7.91	7.79	8.2	8.01	7.76
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	6.09	6.02	9.03	9.03	8.47	8.47	8.34	8.34	8.34	8.34
FII	0.77	0.74	1.06	1.05	1.29	1.28	1.28	1.26	1.15	1.08
DII	1.09	1.09	1.65	1.68	2.03	2.05	1.99	1.96	2.1	2.2
Public	0.7	0.7	1.06	1.04	1.02	1.01	0.98	1.03	1.01	0.98
Others	0	0	0	0	0	0	0	0	0	0
Total	8.65	8.54	12.81	12.81	12.81	12.81	12.59	12.59	12.59	12.59

Pros

Company has a good return on equity (ROE) track record: 3 Years ROE 21%
Debtor days have improved from 188.77 to 157.44days.
Company has reduced debt.
Company is almost debt free.

Cons

Stock is trading at 8.4 times its book value.
The company has delivered a poor profit growth of 4% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Ajanta Pharma News

IPO

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Ajanta Pharma

Add Watchlist

Ajanta Pharma Research see more...

Overview Inc. Year: 1979Industry: Pharmaceuticals & Drugs

Ajanta Pharma Share Price

Alert Data

Quarterly Price

Peer Comparison

Ajanta Pharma Quarterly Results

Ajanta Pharma Profit & Loss

Growth Rates

Ajanta Pharma Balance Sheet

Ajanta Pharma Cash Flow

Ajanta Pharma Ratios

Ajanta Pharma Shareholding Pattern

Ajanta Pharma News

IPO

Stocx: India's #1 Marketplace to Find Your Winning Stock

Please Login!

Error!